Special Offers
100% Performance Guaranteed
Key Specifications Table
| Species Reactivity | Key Applications | Host | Format | Antibody Type |
|---|---|---|---|---|
| H | IH(P), WB | M | Culture Supernatant | Monoclonal Antibody |
| Description | |
|---|---|
| Catalogue Number | MABS434 |
| Description | Anti-PCSK9 Antibody, clone 9B3.1 |
| Alternate Names |
|
| Background Information | Proprotein convertase subtilisin/kexin type 9 (UniProt Q8NBP7; also known as NARC-1, Neural apoptosis-regulated convertase 1, PC9, Proprotein convertase 9, Subtilisin/kexin-like protease PC9) is encoded by the PCSK9 (also known as HCHOLA3, LDLCQ1, NARC1, PSEC0052) gene (Gene ID 255738) in human. PCSK9 is a proprotein convertase expressed in the hepatocyte and to a lesser extent also in the intestine and kidney. PCSK9 is produced as a precusor protein with a signal peptide (a.a.1-30) and a propeptide sequence (a.a. 31-152) that undergo posttranslational autocleavage to yield the mature PCSK9 protein (a.a. 153-692). PCSK9 utilizes its proteolytic activity only in autocleavage during protein maturation, a process that is necessary for its secretion. Once secreted into the plasma, PCSK9 binds LDL receptor (LDL-R), causing LDL-R endocytosis and lysosomal degradation, effectively reducing cell surface LDL-R population. Both PCSK9 and LDL-R are transcribed by sterol-responsive element-binding protein 2 (SREBP2) in response to lowered cellular cholesterol level, allowing enhanced, but not unfettered cellular cholesterol uptake by LDL-R. PCSK9 also binds very low density lipoprotein (VLDL) receptor and apolipoprotein E receptor 2, and thereby interferes with uptake of circulating VLDL particles and apolipoproteins. |
| Product Information | |
|---|---|
| Format | Culture Supernatant |
| Presentation | Mouse IgG2a hybridoma culture supernatant without azide. |
| Quality Level | MQ100 |
| Applications | |
|---|---|
| Application | Detect PCSK9 using this mouse monoclonal Anti-PCSK9, clone 9B3.1 Antibody, Cat. No. MABS434, validated for use in Immunohistochemistry (Paraffin) and Western Blotting. |
| Key Applications |
|
| Application Notes | Immunohistochemistry Analysis: A 1:50 dilution from a representative lot detected NARC-1 (PCSK9) in human colon cancer, normal kidney and prostate tissue sections. Western Blotting Analysis: A 1:500 dilution from a representative lot detected NARC-1 (PCSK9) in 10 µg of human colon tumor tissue lysate. |
| Biological Information | |
|---|---|
| Immunogen | GST-tagged recombinant human mature NARC-1 (PCSK9) N-terminal fragment. |
| Clone | 9B3.1 |
| Concentration | Please refer to lot specific datasheet. |
| Host | Mouse |
| Specificity | Clone 9B3.1 detects the precursor and mature forms of human PCSK9 (NARC-1) by targeting an epitope within the N-terminal region of the mature sequence. |
| Isotype | IgG2aκ |
| Species Reactivity |
|
| Antibody Type | Monoclonal Antibody |
| Entrez Gene Number |
|
| Gene Symbol |
|
| Purification Method | Unpurified |
| UniProt Number |
|
| Molecular Weight | ~75/60 kDa observed. 74.29 kDa (prepro-form; a.a. 1-692), 71.05 kDa (pro-form; a.a. 31-692), and 57.29 kDa (mature form; a.a. 153-692) calculated. Uncharacterized bands may be observed in some lysate(s). |
| Product Usage Statements | |
|---|---|
| Quality Assurance | Evaluated by Western Blotting in SW480 cell lysate. Western Blotting Analysis: A 1:500 dilution of this hybridoma culture supernatant detected NARC-1 (PCSK9) in 10 µg of SW480 human colon adenocarcinoma cell lysate. |
| Usage Statement |
|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | Stable for 1 year at -20°C from date of receipt. Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance. |
| Packaging Information | |
|---|---|
| Material Size | 200 µL |